This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Health Care

A Battle Rages Over Whether an Old Drug Can Be New Again

A Battle Rages Over Whether an Old Drug Can Be New Again

  • Tickers in this article:
  • UTHR
  • NVS

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder.

02/27/15 - 01:58 PM EST

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

After a robust year of mega-deals in 2014, mid-size device makers are expected to seek partners, fueling even further consolidation.

02/27/15 - 12:51 PM EST

Try Jim Cramer's Action Alerts PLUS
February 27 Premarket Briefing: 10 Things You Should Know February 27 Premarket Briefing: 10 Things You Should Know

February 27 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are sinking Friday as investors awaited an influx of data on U.S. GDP, manufacturing and consumer sentiment.

02/27/15 - 08:53 AM EST

Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences

Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

02/27/15 - 06:00 AM EST

Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal

Cyberonics, Sorin Plan to Merge in Latest Tax Inversion Deal

Medical device manufacturers Cyberonics and Sorin will join forces and move their headquarters to the U.K. in a deal propelled by the search for lower corporate taxes.

02/26/15 - 11:54 AM EST

February 26 Premarket Briefing: 10 Things You Should Know

February 26 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are bouncing upward on Thursday, as investors await a flood of data on consumer prices, jobless claims and housing.

02/26/15 - 08:49 AM EST

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.

02/25/15 - 11:47 AM EST

February 25 Premarket Briefing: 10 Things You Should Know

February 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are mixed as investors await Federal Reserve Chair Janet Yellen's continued testimony before Congress, and as the Nasdaq reaches toward 5,000.

02/25/15 - 08:17 AM EST

Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm

Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm

It is no pipe dream that the stock could trade to $240

02/24/15 - 11:39 AM EST

February 24 Premarket Briefing: 10 Things You Should Know

February 24 Premarket Briefing: 10 Things You Should Know

U.S. stock futures aren't moving much as investors await Federal Reserve Chair Janet Yellen's Congressional testimony.

02/24/15 - 06:42 AM EST

Valeant Surges on Salix Acquisition: What Wall Street's Saying

Valeant Surges on Salix Acquisition: What Wall Street's Saying

  • Tickers in this article:
  • SLXP
  • VRX

Investors are cheering for Valeant Pharmaceutical's planned $14.5 billion acquisition of Salix Pharmaceuticals, but Salix shareholders were hoping for more.

02/23/15 - 11:51 AM EST

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

Bristol-Myers Commits Up to $1.25 Billion to Add Flexus Cancer Therapies

The pharma giant is making an upfront payment of $800 million and committing to up to $450 million more in milestone payments.

02/23/15 - 11:14 AM EST

February 23 Premarket Briefing: 10 Things You Should Know

February 23 Premarket Briefing: 10 Things You Should Know

U.S. stock futures look negative, although stocks ended last week at a record high.

02/23/15 - 07:20 AM EST

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

  • Tickers in this article:
  • VRX
  • SLXP

Canada's Valeant Pharma agreed to buy Salix Pharma in cash deal valued at about $14.5 billion, the companies said Sunday.

02/22/15 - 08:37 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs